Related Experiment Video
Updated: Jun 26, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Evaluating combination therapies for asthma: pros, cons, and comparative benefits
1Department of Respiratory Medicine & Allergology, University Hospital, Lund, Sweden. leif.bjermer@med.lu.se
Therapeutic Advances in Respiratory Disease
|January 7, 2009
Summary
Inhaled corticosteroid (ICS) combination therapies with long-acting beta2 agonists (LABA) or leukotriene receptor antagonists (LTRA) offer benefits for asthma control. Individualized management is key due to varied outcomes and patient phenotypes.
Area of Science:
- Pulmonology
- Allergy and Immunology
- Pharmacology
Background:
- Combination therapies with inhaled corticosteroids (ICS) are standard for asthma management.
- Long-acting beta2 agonists (LABA) and leukotriene receptor antagonists (LTRA) offer complementary benefits when combined with ICS.
- LABA and LTRA possess distinct mechanisms of action, influencing their efficacy in asthma control.
Purpose of the Study:
- To compare ICS/LABA and ICS/LTRA regimens using recent clinical trial data.
- To evaluate the efficacy of these combinations on clinical outcomes and quality of life.
- To discuss the role of asthma phenotypes in therapy selection and individualized management.
Main Methods:
- Comparative analysis of recent clinical trial data.
- Evaluation of efficacy across diverse clinical and quality of life endpoints.
- Review of new dosing strategies, including adjustable and single-inhaler therapies.
Main Results:
- Both ICS/LABA and ICS/LTRA demonstrate efficacy in asthma control.
- Treatment choice impacts various clinical outcomes and patient-reported quality of life.
- Specific asthma phenotypes may respond differently to each regimen.
Conclusions:
- Individualized asthma management is crucial, considering patient phenotypes and treatment outcomes.
- The choice between ICS/LABA and ICS/LTRA should be tailored to individual patient needs.
- Emerging dosing strategies may further personalize asthma therapy.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...